

January 09, 2026

BSE Limited
 Corporate Relationship Department
 Phiroze Jeejeebhoy Towers
 25th floor, Dalal Street
 Mumbai - 400 001
 Scrip Code: 543245

National Stock Exchange of India Limited
 Listing Department
 Exchange Plaza, 5th floor
 Plot no. C-1, Block G, Bandra Kurla Complex Bandra
 (East), Mumbai - 400 051
 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Wednesday, January 28, 2026**, *inter alia* to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.

Trading Window:

In continuation to our earlier intimation dated December 26, 2025; this is to inform you that the trading window, which was closed from **Saturday, December 27, 2025**, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Saturday, January 31, 2026**.

Earnings Call:

The Investor/Analyst call will be held on **Wednesday, January 28, 2026**, at 18:30 Hrs (IST). Further details will be intimated to the stock exchanges and published on the Company's website (www.glandpharma.com) in due course.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer